Skip to main content
S&P 5007,743.98+0.28%DOW52,475.10+0.19%NASDAQ26,549.85+0.27%BTC$81,183.00+0.46%ETH$2,356.16+0.38%GOLD$4,078.40+0.66%OIL$101.97-0.79%
Smart Investors Daily
SID Premium
CY

NASDAQ · CYTK

Cytokinetics, Incorporated

Healthcare · Biotechnology

$61.52

Down-$0.24 (-0.39%)

Updated Oct 28, 2026, 9:46 PM

SID Score

4.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
7.23B
P/E ratio
-9.7
Dividend yield
0.00%
52-week range
$58.05 – $88.31
Volume
1.15M
Avg. volume
2.02M

Price performance · CYTK

CYTK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

CYTK closed at $61.52 after 21 trading sessions, down 6.28% for the selected period.

Last close
$61.52
Period change
-6.28%
Period low
$60.73
Period high
$65.91
Daily close
View OHLC price history
CYTK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$60.68$61.83$60.47$61.521.15M
Oct 26, 2026$61.45$61.89$60.475$60.73783.24K
Oct 23, 2026$62.01$62.44$60.8903$61.23985.63K
Oct 22, 2026$63.01$64.07$61.94$62.332.06M
Oct 21, 2026$64.30$64.78$62.4583$62.861.08M
Oct 20, 2026$63.13$64.755$62.88$63.951.05M
Oct 19, 2026$62.06$63.605$61.84$62.651.91M
Oct 16, 2026$63.90$63.90$61.685$61.951.2M
Oct 15, 2026$64.81$65.57$63.81$63.921.67M
Oct 14, 2026$61.62$64.01$60.99$63.432.1M
Oct 13, 2026$62.32$63.05$61.50$61.621.94M
Oct 12, 2026$62.48$63.50$62.13$62.791.25M
Oct 9, 2026$61.87$63.03$61.59$62.911.12M
Oct 8, 2026$60.31$62.79$59.785$62.012.59M
Oct 7, 2026$61.085$62.05$60.1546$61.122.4M
Oct 6, 2026$62.20$62.525$60.68$61.353.23M
Oct 5, 2026$65.60$65.755$62.19$62.703.23M
Oct 2, 2026$66.45$66.91$64.49$65.602.65M
Oct 1, 2026$65.73$67.27$65.30$65.621.72M
Sep 30, 2026$65.90$66.92$65.25$65.912.98M
Sep 29, 2026$65.91$66.52$64.38$65.642.4M

Latest CYTK news

The latest Smart Investors Daily articles mentioning CYTK.

Stock researchCompany · Overview

CYTK research

Overview

Company profile and research snapshot.

Company profile

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$79.75
Implied upside
—
Analysts
—
CYTK recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
Oct 16, 2026William BlairOutperform—
Oct 8, 2026RBC CapitalOutperform—
Aug 31, 2026HC Wainwright & Co.Buy—
Aug 13, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Cytokinetics to Announce Third Quarter Results on November 4, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of C

Yahoo · Oct 19, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the R

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By